SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate principal amount of 1.75% convertible senior notes due 2031 in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The aggregate principal amount of the offering was increas ...

Accessibility StatementSkip Navigation SAN DIEGO, Sept. 16, 2025 /PRNewswire/ -- Robbins LLPÂ reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Savara Inc. (NASAQ: SVRA) securities between March 7, 2024 and May 23, 2025. Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. The Company's lead product candidate is MOLBREEVI (also referred to as "molgramostim"), an inhaled granulocyte-macrophage colony ...

临床试验进展 - 首例患者已在HTL0039732的2a期临床试验中完成给药 该试验针对晚期实体瘤患者[1] - 推进至2a期基于1期试验成功完成 确定了HTL0039732与atezolizumab联合使用的安全耐受剂量[2] - 1期试验显示早期疗效令人鼓舞 包括两种不同肿瘤类型患者中出现两例经确认的部分缓解[3] 药物机制与特性 - HTL0039732是一种口服小分子EP4拮抗剂 通过阻断前列腺素E2(PGE2)的EP4受体信号传导发挥作用[4] - 该药物靶向EP4可阻断PGE2在肿瘤微环境中的作用 增强免疫系统检测和控制癌细胞的能力[4] - 该药物被研究用于治疗对当前免疫疗法反应不佳的癌症类型[4] 试验设计与合作 - 2a期试验将扩展至四个患者队列 包括微卫星稳定结直肠癌 胃或胃食管结合部腺癌 透明细胞肾细胞癌和转移性去势抵抗性前列腺癌[6] - 癌症研究中心UK药物开发中心赞助并管理该试验 由剑桥大学和伦敦国王学院的首席研究员领导[5] - 试验在Addenbrooke医院进行 并通过实验癌症医学中心网络的多家中心招募患者[5] 公司背景与研发管线 - Nxera是一家技术驱动的生物制药公司 专注于为日本和全球未满足医疗需求的患者开发 specialty medicines[9] - 公司建立了新一代商业化业务 在日本和亚太地区开发和商业化创新药物 包括多个已上市产品[9] - 公司拥有超过30个活跃研发项目 涵盖从发现到后期临床阶段 专注于肥胖与代谢疾病 神经学/神经精神病学和免疫学与炎症领域[10] 合作伙伴实力 - 癌症研究中心UK药物开发中心在30年间已将超过170种潜在新型抗癌药物推进至临床试验[11] - 该中心已有6种新药物上市 包括用于脑癌的temozolomide 用于前列腺癌的abiraterone和用于卵巢癌的rucaparib[11] - 目前该中心拥有16个处于临床前开发 1期或早期2期临床试验的项目组合[11]

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that an investor filed a class action lawsuit on behalf of purchasers of securities of Savara Inc. (NASDAQ: SVRA), between March 7, 2024 and May 23, 2025, both dates inclusive (the "Class Period†). Savara is a clinical- stage biopharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allega. ...

MONTREAL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today that the Company has obtained the final order from the Superior Court of Québec (Commercial Division) approving the previously-announced plan of arrangement (the “Arrangement”) under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the “Purchaser”), an affiliate of ...

Secures Incentive Offer of up to US$255K to Establish Operations in IndianapolisTORONTO and HAIFA, Israel and INDIANAPOLIS, Sept. 16, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical innovator in exosome-based regenerative therapies, is pleased to announce that its U.S. subsidiary, Exo-Top Inc. (“Exo-Top”), is planning to establish its first U.S. commercial exosome production facility in Indianapolis, Indiana. The Indian ...

核心观点 - 公司展示其新一代法尼基转移酶抑制剂KO-2806（darlifarnib）与PI3Kα抑制剂、KRAS抑制剂及抗血管生成酪氨酸激酶抑制剂（TKIs）联用的潜力 旨在解决肿瘤治疗中的耐药性问题[1][2][4] - 临床前数据表明KO-2806通过抑制mTOR信号通路增强联合疗法的抗肿瘤活性 覆盖非小细胞肺癌、结直肠癌、肾细胞癌及神经内分泌肿瘤等多种适应症[1][4] - 公司计划在2025年10月ESMO大会上公布初步临床数据 并预计KO-2806组合疗法每年可能覆盖美国超过20万例患者[1][4][5] 临床前研究结果 - KO-2806作为新一代FTI 在临床前模型中显示出优于第一代候选药物的效力、药代动力学和理化特性[4] - 在基因定义的体内肿瘤模型中 FTIs能有效抑制mTOR信号通路 与抗血管生成TKIs、PI3Kα抑制剂及KRAS抑制剂联用时增强抗肿瘤活性[4] - 在非小细胞肺癌和结直肠癌的临床前复发模型中 KO-2806使肿瘤对突变选择性或泛KRAS抑制剂重新敏感[4] - 多靶向疗法类别的临床前结果显示出广泛的机制重叠 表明KO-2806具有跨类别应用的潜力[4] 临床开发计划 - 公司将于2025年10月ESMO大会上进行三项FTI临床数据展示 包括试验原理、设计和目标[4] - 第二次分析师/投资者活动定于2025年10月18日太平洋时间上午10:30举行 重点讨论ESMO大会的临床数据[5] - KO-2806与标准治疗药物（如cabozantinib）联用 针对肾细胞癌和神经内分泌肿瘤的治疗缺口[4] 市场潜力 - KO-2806组合疗法预计每年可覆盖美国超过20万例患者 适应症包括KRAS和PI3Kα突变癌症（如非小细胞肺癌、结直肠癌、乳腺癌）[4]

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best drug stocks to buy right now. On September 5, RBC Capital raised the firm’s price target on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to $149 from $144 while keeping an Outperform rating on the shares. Neurocrine Biosciences, Inc. (NBIX): Among Small-Cap Healthcare Stocks Hedge Funds is Buying The firm told investors in a research note that, according to its latest analysis of prescription trends, Crenessity’s strong launch is expected to con ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best drug stocks to buy right now. On September 8, BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb Company (NYSE:BMY), retaining the price target of $47.00. Why Investors View Bristol‑Myers Squibb (BMY) as a Safe Dividend Stock for Income The analyst attributed the rating to the performance of Cobenfy, the company’s new product, in the market, stating that its growth has been stable with a modest percentage increase ...

Merck & Co., Inc. (NYSE:MRK) is one of the best drug stocks to buy right now. On September 10, Leerink Partners analyst Daina Graybosch maintained a bullish stance on Merck & Co., Inc. (NYSE:MRK), giving the stock a Buy rating. Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup The analyst gave the optimistic rating due to Merck & Co., Inc.’s (NYSE:MRK) strategic position in the competitive landscape of antibody-drug conjugates (ADCs) to treat extensive-stage small cell lung cancer ( ...